Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $7.33.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 7,471 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $4.04, for a total value of $30,182.84. Following the transaction, the chief executive officer now directly owns 3,176,788 shares of the company’s stock, valued at approximately $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Joshua B. Cohen sold 21,490 shares of the business’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $74,570.30. Following the sale, the chief executive officer now owns 3,355,280 shares of the company’s stock, valued at approximately $11,642,821.60. This represents a 0.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,980 shares of company stock valued at $252,769. Company insiders own 11.70% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Blue Trust Inc. increased its holdings in Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth $45,000. Alpine Global Management LLC bought a new position in Amylyx Pharmaceuticals in the 4th quarter worth $45,000. RPO LLC purchased a new position in Amylyx Pharmaceuticals during the fourth quarter valued at $46,000. Finally, EntryPoint Capital LLC bought a new stake in Amylyx Pharmaceuticals during the fourth quarter valued at about $53,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Trading Down 2.3 %

NASDAQ AMLX opened at $3.43 on Monday. Amylyx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $7.27. The stock’s fifty day moving average price is $3.55 and its 200-day moving average price is $4.05. The stock has a market cap of $303.90 million, a P/E ratio of -0.90 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million for the quarter. As a group, analysts forecast that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.